Welcome to our dedicated page for MedWellAI SEC filings (Ticker: MWAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MedWellAi, Inc. (MWAI) is an AI-driven healthcare and wellness company whose business operations include B2B pharmaceutical distribution, telemedicine platforms under the TeleMD.Ai brand, and health and wellness real estate and software solutions. While no SEC filings are listed in the available data here, investors typically look to regulatory documents to understand how a company like MedWellAi presents its business model, risks, and financial details in a formal reporting context.
For a company operating in healthcare technology and wellness, key SEC filings often include annual reports on Form 10-K and quarterly reports on Form 10-Q, which generally describe operating segments such as MedWell USA, LLC, MedWell Direct, LLC dba TeleMD.Ai, and MedWell Facilities, LLC. These reports usually explain how B2B e-commerce distribution, telemedicine platforms, and health-focused real estate and software contribute to the overall business. They also tend to discuss agreements with technology partners and pharmaceutical suppliers, as referenced in MedWellAi’s public news releases.
Other important filings for a company in this space can include current reports on Form 8-K, which may document events such as corporate rebranding from Integrated Ventures, Inc. to MedWellAi, Inc., changes in trading symbols, or significant contracts like the software development agreement with BrighterMD. For investors interested in ownership and governance, insider transaction reports on Form 4 and proxy statements on Schedule 14A can provide insight into equity holdings and executive or director compensation policies.
On Stock Titan’s SEC filings page for MWAI, users can access MedWellAi’s regulatory disclosures as they become available and use AI-powered summaries to interpret complex documents. These tools help explain the structure of MedWellAi’s AI-driven healthcare ecosystem, highlight material agreements and risk factors, and clarify how its telemedicine, pharmaceutical distribution, and wellness real estate activities are reflected in formal SEC reporting.
MedWellAI, Inc. reports sharply higher revenue but continues to operate at a loss with serious liquidity pressure. For the six months ended December 31, 2025, revenue rose to
Despite this growth, MedWellAI recorded a net loss attributable to shareholders of
The company has exited digital asset mining, pivoting to AI-driven healthcare and wellness through pharmaceutical product distribution and health-focused real estate. Management discloses that these recurring losses and the large deficit raise substantial doubt about its ability to continue as a going concern without new debt or equity financing.
MedWellAI, Inc. notifies the SEC that it could not file its Quarterly Report on Form 10-Q for the three and six months ended
The company states it needs additional time to complete disclosures and analyses. The filing notes an expected increase in product revenue to
MedWellAI, Inc. (MWAI) filed its quarterly report and reported a shift toward commission-based health and wellness distribution while posting a smaller loss. Revenue was
Liquidity remains tight. Cash was
MedWellAI, Inc. reports a difficult year with material impairments, debt defaults and a large accumulated deficit that raise substantial doubt about its ability to continue as a going concern. The company acquired 51% of Healthy Lifestyle and recorded a $670,329 goodwill impairment after deciding to abandon that business; earn-out targets tied to Healthy Lifestyle were not met so no post-closing payments are due. The company reported an accumulated deficit of $88,673,880 and disclosed operations that produced cash shortfalls. A note payable went into default and the lender reduced default interest to 10% effective April 1, 2024; interest expense of $50,694 and $81,389 was recorded in fiscal 2025 and 2024. Management also issued 50,000 Series B preferred shares to a related party, valued on an as-converted basis at $8,300,000, convertible at 100:1. The filing discloses discontinued mining operations and other one-time adjustments but lacks full, contiguous financial tables in this extract.